Evidence map›Paper›PMID 39469630›Full record

ArticleFrontiers in pharmacology2024

GABA Type A receptors expressed in triple negative breast cancer cells mediate chloride ion flux.

J Bundy, Y Ahmed, S Weller, J Nguyen, J Shaw, I Mercier, A Suryanarayanan

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

J BundyDepartment of Pharmaceutical Sciences, Philadelphia College of Pharmacy, Saint Joseph's University, Pharmacology and Toxicology Center, Philadelphia, PA, United States.
Y AhmedDepartment of Pharmaceutical Sciences, Philadelphia College of Pharmacy, Saint Joseph's University, Pharmacology and Toxicology Center, Philadelphia, PA, United States.
S WellerDepartment of Pharmaceutical Sciences, Philadelphia College of Pharmacy, Saint Joseph's University, Pharmacology and Toxicology Center, Philadelphia, PA, United States.
J NguyenDepartment of Pharmaceutical Sciences, Philadelphia College of Pharmacy, Saint Joseph's University, Pharmacology and Toxicology Center, Philadelphia, PA, United States.
J ShawDepartment of Pharmaceutical Sciences, Philadelphia College of Pharmacy, Saint Joseph's University, Pharmacology and Toxicology Center, Philadelphia, PA, United States.
I MercierDepartment of Pharmaceutical Sciences, Philadelphia College of Pharmacy, Saint Joseph's University, Pharmacology and Toxicology Center, Philadelphia, PA, United States.
A SuryanarayananDepartment of Pharmaceutical Sciences, Philadelphia College of Pharmacy, Saint Joseph's University, Pharmacology and Toxicology Center, Philadelphia, PA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Triple negative breast cancer (TNBC) is known for its heterogeneous nature and aggressive onset, limited unresponsiveness to hormone therapies and immunotherapy as well as high likelihood of metastasis and recurrence. Since no targeted standard treatment options are available for TNBC, novel and effective therapeutic targets are urgently needed. Ion channels have emerged as possible novel therapeutic candidates for cancer therapy. We previously showed that GABA

Indexed as

bicucullineGABA beta3GABA type A receptorion fluxligand gated chloride channelTNBC (triple negative breast cancer)

Identifiers

PMID39469630
PMCPMC11513581

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.